Panic attacks and psychiatric comorbidity in multiple sclerosis: reinterpreting a 2004–2006 Georgian case-control study in the context of contemporary evidence

Authors

DOI:

https://doi.org/10.66636/gmj.v1.i2.a111

Keywords:

Multiple Sclerosis, Panic Disorder, Anxiety, Psychiatric Comorbidity, Case-Control Studies, Georgia

Abstract

Background  Georgian evidence on psychiatric comorbidity in multiple sclerosis (MS) is sparse. A previously unpublished single-centre Batumi case-control dataset from 2004–2006 is reanalysed here and reinterpreted in the light of the 2026 clinical framework — current diagnostic criteria, disease-modifying therapies (DMTs), validated psychiatric instruments, and mechanistic neuroimaging — to establish a pre-DMT-era Georgian baseline against which contemporary MS care can be benchmarked.

Methods  In this single-centre, hospital-based case-control study conducted between 2004 and 2006 at the High Technology Hospital Medical Centre (Batumi, Georgia), 30 adults with clinically confirmed MS (16 women, 14 men; age range 20–75 years; disease duration 1–5 years) were compared with 30 age- and sex-matched healthy controls. Anxiety was assessed using the Sheehan Patient-Rated Anxiety Scale. Frequency of panic attacks, impairment in daily functioning, social behaviour, capability changes, suicidal ideation, and somato-vegetative symptoms were recorded through structured clinical interview. Between-group comparisons used Fisher’s exact test and chi-square tests; risk was expressed as odds ratios (ORs) with 95% confidence intervals (CIs).

Results  The overall distribution of panic-attack frequency differed significantly between groups (χ² = 8.83; df = 2; p = 0.012). Any panic attacks (≥5 per month) were reported by 26/30 (86.7%) patients and 17/30 (56.7%) controls (OR 4.97; 95% CI 1.39–17.82; p = 0.020). Compared with controls, patients had significantly higher odds of impaired daily functioning (OR 7.56; 95% CI 2.41–23.75; p = 0.001), capability changes (OR 4.67; 95% CI 1.57–13.87; p = 0.009), and social-behaviour disturbance (OR 3.76; 95% CI 1.24–11.39; p = 0.033). Suicidal ideation was more frequent in the MS group (36.7% vs 13.3%; OR 3.76; 95% CI 1.04–13.65; p = 0.072).

Conclusions  Georgian adults with MS in 2004–2006 showed strikingly elevated odds of panic attacks, functional impairment, and suicidal ideation compared with matched controls. The magnitude of this burden, reinterpreted against 2026 standards, plausibly reflects MS lived in the near-absence of modern care. These data establish a pre-DMT-era Georgian baseline and argue for urgent implementation of integrated psychiatric screening, expanded DMT access, and a contemporary multicentre Georgian MS registry.

Keywords  multiple sclerosis; panic disorder; anxiety; psychiatric comorbidity; case-control studies; Georgia (Republic)

References

1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169–80. https://doi.org/10.1056/NEJMra1401483

2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17. https://doi.org/10.1016/S0140-6736(08)61620-7

3. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622–36. https://doi.org/10.1016/S0140-6736(18)30481-1

4. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–21. https://doi.org/10.1177/1352458520970841

5. Portaccio E, Fonderico M, Hemmer B, Hauser SL, Magyari M, Tedeholm H, et al. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Eur. 2024;44:100977. https://doi.org/10.1016/j.lanepe.2024.100977

6. Koch-Henriksen N, Thygesen LC, Stenager E, Laursen B, Magyari M. Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women. Neurology. 2018;90(22):e1954–63. https://doi.org/10.1212/WNL.0000000000005612

7. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73. https://doi.org/10.1016/S1474-4422(17)30470-2

8. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86. https://doi.org/10.1212/WNL.0000000000000560

9. Liu Z, Liao Q, Wen H, Zhang Y. Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. Autoimmun Rev. 2021;20(6):102826. https://doi.org/10.1016/j.autrev.2021.102826

10. Marrie RA, Reingold S, Cohen J, Stuve O, Trojano M, Sorensen PS, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler. 2015;21(3):305–17. https://doi.org/10.1177/1352458514564487

11. Marrie RA, Fisk JD, Tremlett H, Wolfson C, Warren S, Tennakoon A, et al. Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology. 2015;85(22):1972–9. https://doi.org/10.1212/WNL.0000000000002174

12. Boeschoten RE, Braamse AMJ, Beekman ATF, Cuijpers P, van Oppen P, Dekker J, et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci. 2017;372:331–41. https://doi.org/10.1016/j.jns.2016.11.067

13. Butler E, Matcham F, Chalder T. A systematic review of anxiety amongst people with multiple sclerosis. Mult Scler Relat Disord. 2016;10:145–68. https://doi.org/10.1016/j.msard.2016.10.003

14. Peres DS, Rodrigues P, Viero FT, Frare JM, Kudsi SQ, Meira GM, et al. Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: a systematic review and meta-analysis. Brain Behav Immun Health. 2022;24:100484. https://doi.org/10.1016/j.bbih.2022.100484

15. Zhang X, Song Y, Wei Z, Chen X, Zhuang X, Yi L. The prevalence and risk factors of anxiety in multiple sclerosis: a systematic review and meta-analysis. Front Neurosci. 2023;17:1120541. https://doi.org/10.3389/fnins.2023.1120541

16. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler. 2007;13(1):67–72. https://doi.org/10.1177/1352458506071161

17. Algin DI, Kilicoglu A, Koplay M. Panic disorder as presenting symptoms of multiple sclerosis. Ann Gen Psychiatry. 2010;9(Suppl 1):S138. https://doi.org/10.1186/1744-859X-9-S1-S138

18. Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol. 2014;10(9):507–17. https://doi.org/10.1038/nrneurol.2014.139

19. Solaro C, Gamberini G, Masuccio FG. Depression in multiple sclerosis: epidemiology, aetiology, diagnosis and treatment. CNS Drugs. 2018;32(2):117–33. https://doi.org/10.1007/s40263-018-0489-5

20. Ellwardt E, Muthuraman M, Gonzalez-Escamilla G, Chirumamilla VC, Luessi F, Bittner S, et al. Network alterations underlying anxiety symptoms in early multiple sclerosis. J Neuroinflammation. 2022;19(1):119. https://doi.org/10.1186/s12974-022-02476-0

21. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology. 2002;59(5):674–8. https://doi.org/10.1212/wnl.59.5.674

22. Feinstein A, Pavisian B. Multiple sclerosis and suicide. Mult Scler. 2017;23(7):923–7. https://doi.org/10.1177/1352458517702553

23. Viner R, Patten SB, Berzins S, Bulloch AGM, Fiest KM. Prevalence and risk factors for suicidal ideation in a multiple sclerosis population. J Psychosom Res. 2014;76(4):312–6. https://doi.org/10.1016/j.jpsychores.2013.12.010

24. McKay KA, Tremlett H, Fisk JD, Zhang T, Patten SB, Kastrukoff L, et al. Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology. 2018;90(15):e1316–23. https://doi.org/10.1212/WNL.0000000000005302

25. Kowalec K, McKay KA, Patten SB, Fisk JD, Evans C, Tremlett H, et al. Comorbidity increases the risk of relapse in multiple sclerosis: a prospective study. Neurology. 2017;89(24):2455–61. https://doi.org/10.1212/WNL.0000000000004716

26. Thormann A, Sørensen PS, Koch-Henriksen N, Laursen B, Magyari M. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. Neurology. 2017;89(16):1668–75. https://doi.org/10.1212/WNL.0000000000004508

27. Fiest KM, Walker JR, Bernstein CN, Graff LA, Zarychanski R, Abou-Setta AM, et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord. 2016;5:12–26. https://doi.org/10.1016/j.msard.2015.10.004

28. Minden SL, Feinstein A, Kalb RC, Miller D, Mohr DC, Patten SB, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Neurology. 2014;82(2):174–81. https://doi.org/10.1212/WNL.0000000000000013

29. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. PLoS Med. 2007;4(10):e296. https://doi.org/10.1371/journal.pmed.0040296

30. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4. https://doi.org/10.1001/jama.2013.281053

31. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11 Suppl 3:89–95. https://doi.org/10.1097/00004850-199606003-00015

Cover of the Georgian Medical Journal (GMJ), Volume 1, Issue 2 (2026), titled “Health Systems Performance and Quality of Care: Measurement, Improvement, and Outcomes,” with a blue world map background representing global health connectivity. Includes the themes “Quality, Safety, Results” and the publisher Public Health Institute of Georgia.

Downloads

Published

05/09/2026

How to Cite

Kekenadze, M., Vashadze, S., Saparidze, K., Gorgiladze, K., & Varshanidze, K. (2026). Panic attacks and psychiatric comorbidity in multiple sclerosis: reinterpreting a 2004–2006 Georgian case-control study in the context of contemporary evidence. Georgian Medical Journal, 1(2), 1–12. https://doi.org/10.66636/gmj.v1.i2.a111

Issue

Vol. 1 No. 2 (2026): Health Systems Performance and Quality of Care

Section

Original Research

License

Copyright (c) 2026 Mariam Kekenadze, Shorena Vashadze, Ketevan Saparidze, Keso Gorgiladze, Khatuna Varshanidze

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Open Access · CC BY 4.0

This article is published open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.

You are free to: share and adapt the work for any purpose, even commercially.
Conditions: provide appropriate credit to the authors and the Georgian Medical Journal (GMJ), link to the licence, and indicate if changes were made. Do not apply legal terms or technological measures that legally restrict others from doing anything the licence permits.
Licence: creativecommons.org/licenses/by/4.0  ·  Legal code: creativecommons.org/licenses/by/4.0/legalcode

Third-party material. Images or other content credited to a third party are not covered by CC BY 4.0; permission must be obtained from the rights holder for reuse beyond statutory exceptions.

Authors' rights. Authors retain copyright. First publication rights are granted to GMJ.

Data and code. Where provided, datasets or code may carry their own licences; please follow the licence stated in the article or repository record.

Recommended citation
Author(s). Title. Georgian Medical Journal (GMJ) Year;Volume(Issue):Pages. CC BY 4.0. DOI: 10.66636/xxxxx

Similar Articles

1 2 3 4 5 6 7 8 9 10 11 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)